Gram-negative aerobic bacilli currently account for a substantial percentage of nosocomial infections (2, 6a) . Of this bacterial grouping, Klebsiella spp. are a leading cause of morbidity and mortality (13, 17) . Several hospitalized patient populations are at increased risks to infections with Klebsiella spp., including neonates (14, 24) in which frequent epidemics have been reported, patients receiving respiratory therapy (15, 19) , and urological (4) and burn wound patients (16, 21) . The occurrence of Klebsiella strains displaying multiple-drug resistance (3, 28) has greatly complicated therapy. Mortality rates, even in the face of intensive chemotherapy, may approach or exceed 50% (13, 17) .
Several Klebsiella somatic antigens, including capsular polysaccharide (PS) (6, 8, 12, 26) , pili (11) , and a heat-labile cell surface antigen of an unknown nature (6) , have been implicated as important virulence factors. Of these, PS has been most intensely studied. Possession of a large capsule appears to be essential for virulence of Klebsiella pneumoniae in several animal models (8, 10) . Anti-PS antibody, elicited in response to immunization either with whole-cell or ribosomal vaccines, confers good levels of protection against a live challenge (6, 12, 26, 27) . To date, the efficacy of systemically administered anti-PS antibody has not been evaluated.
In the present report, the efficacy of intravenously administered antiserum raised against purified PS was evaluated. In light of the importance of Klebsiella spp. as a human burn wound pathogen (16, 21, 24) , protection afforded by anti-PS antibody was studied by using a murine burn wound sepsis Quantitation of bacteria in blood and tissues. Bacterial numbers in the blood, skin (at the challenge site), and liver were quantitated as previously described (7).
Statistical analysis. The mean lethal dose was calculated by the method of Reed and Muench (25) . Statistical The protective capacity of passively transferred anti-PS antibody against fatal K. pneumoniae burn wound sepsis was first evaluated against a low challenge dose (Table 2) . Three independent experiments were performed with control mice receiving normal rabbit serum. In all three determinations, anti-PS provided high levels of protection against lethal infection (P < 0.01 to P = 0.02). Mortality was reduced from 70 to 95% in the control groups to 10 to 35% in groups which received specific antibody. In additional experiments, an equivalent degree of protection (86%) was provided by the passive transfer of either anti-PS antibody or antiserum produced against intact K. pneumoniae KP1-0 cells.
Next, the degree of protection provided against fatal infection by passive therapy with anti-PS antibody was more precisely defined by determining the 50% lethal dose (LD50) for treated and control mice (Table 3 ). More than 50% of the animals in the control group died at the lowest challenge dose in both experiments (<20 organisms). Anti-PS antibody raised the LD50 between 10-and 40-fold. Attempts to further increase the LD50 by the additional administration of specific antisera at various times postchallenge were hampered by the adverse reactions noted in mice which received multiple doses of anti-PS.
All previous experiments were carried out with the antisera administered before the challenge under conditions in which anti-PS antibody was found to be highly protective. Next, the protective capacity of anti-PS antibody was compared when given pre-and postchallenge (Table 4) . Statistically significant protection (P < 0.01) was obtained only when specific antiserum was administered 24 h before the challenge. However, the reduced mortality rates seen when anti-PS antibody was given at +24 h and +48 h (71 and 78%, respectively) as compared with that of the control group (93%) suggested that some protection was provided by specific antibody. Antiserum administered at times later than 48 h did not substantially reduce mortality.
The mechanisms by which anti-PS antibody mediates its protective effect was investigated by monitoring the course of the infection. Preliminary experiments showed that although treatment with specific antiserum (given at -24 h relative to the challenge) only slightly reduced the numbers of bacteria in the skin at the challenge site as compared with that in control mice, bacteremia and liver colonization were markedly reduced (data not shown). Therefore, the development and severity of bacteremia was studied in control and specific antiserum-treated mice (Table 5 ). Bacteremia was first noted at 2 days postchallenge in control mice and persisted throughout the course of the experiment. By day 5, 80% of control mice were bacteremic, with numbers approaching 104/ml of blood. In contrast, the onset of bacteremia was delayed to day 4 in antiserum-treated mice (20% culture positive). Blood cultures were negative on days 5 and 6, with bacteremia again detected on days 7 and 8. However, although between 40 and 60% of mice which received antiserum were bacteremic on these later days, the number of organisms was ca. 1,000-fold less than that concurrently seen in control mice.
Finally, the effect of combined antibiotic and passive therapy on fatal KP1-0 sepsis was evaluated. Gentamicin, administered 24 h postchallenge was ineffective at reducing mortality (Table 6 ). Whereas anti-PS antibody increased the LD50 at least 7-fold, the inclusion of gentamicin into the therapeutic regimen resulted in a further 15-fold increase in the LD50 (to yield a total 105-fold increase in the LD50). DISCUSSION The importance of PS in the pathogenesis of K. pneumoniae experimental infections has been recognized for some time (10) . Although the role of capsule in human infections has not been extensively investigated for Klebsiella species, a direct correlation between the presence of capsular antigen in the blood and a fatal outcome has been demonstrated (23) . The consistently high mortality rates for Klebsiella infections (especially pneumonia) (16) provide an impetus for the development of immunotherapeutic-immunoprophylactic agents. However, relatively few studies have been performed in an attempt to investigate the potential of immunological therapy based on anticapsular antibody (5, 6, 12, 26) . Furthermore, there have been no previous reports on attempts to provide protection against experimental Klebsiella burn infections, even though burn patients are at high risk for Klebsiella infection (16, 21) .
In the present study, anti-PS was produced against a highly purified antigen. This is in contrast to previous reports of experiments in which whole bacterial cells (5, 6) , ribosomal vaccines (12, 26) , or polysaccharide preparations containing appreciable amounts of protein (12) were used to elicit an anti-PS response. Although all of the above studies were able to demonstrate protection mediated by anti-PS antibody, recent findings, which have shown that antibody against an outer membrane protein is also protective (6), emphasize the need for highly purified antigens in the performance of such studies.
Anti-PS administered 24 h before the challenge provided high levels of protectin against fatal K. pneumoniae burn wound sepsis. An equivalent amount of antibody given postchallenge had a greatly diminished protective capacity. This is most likely due to the fact that in the intervening time between the challenge and antibody therapy the bacterial load had increased to levels such that the quantity of antibody given was insufficient. In addition, the release of soluble cell-free PS by replicating bacteria would also act to complex antibody before its coming in contact with the bacterial cell (8) .
In the animal model used in the present study, death was due to overwhelming bacterial sepsis. Anti-PS antibody appeared to mediate its protective effect primarily by preventing or reducing the severity of bacteremia, since bacterial numbers in the skin at the site of infection were comparable in specific antiserum-treated mice and in control mice. Mice which received anti-PS antibody were able to survive infection with low numbers of K. pneumoniae in the blood. Bacteremia in this group was substantially reduced in severity and occurred at a much later time than in control animals. These findings probably stem from a depletion of the transferred antibody which allows for the continued seeding of the blood with bacteria from an extracellular site, most likely from the skin at the site of challenge. Anti-PS antibody would therefore function as opsonic antibody, facilitating the clearance of bacteria -from the blood. This hypothesis is supported by the finding that anti-PS (secretory immunoglobulin A) has been shown to promote the killing of K. pneumoniae in the presence of polymorphonuclear leukocytes (5) .
We found that the administration of gentamicin alone was ineffective in treating an established localized K. pneumoniae KP1-0 infection. However, when gentamicin was used in combination with passive therapy, the protection afforded was substantially greater than that observed only with immunotherapy. Increased protection in this case was most likely due to the action of both agents to prevent sepsis. The synergistic effect noted could well prove to be an important aspect in the future evaluation of passive therapy for the treatment of K. pneumoniae infections.
In two recent reports, infections with Klebsiella species were second only to Pseudomonas aeruginosa as the cause of fatal burn wound sepsis (16, 21) . Passive immunotherapy 
